October 29, 2026

U.S. Blocks Chinese Biotech Shipments Over Forced Labor Concerns

The U.S. government announced it would block shipments from China’s BGI Group, citing concerns over forced labor in Xinjiang. Starting Thursday, U.S. Customs and Border Protection will prohibit goods from BGI Group, BGI Genomics, and MGI Tech. The Department of Homeland Security accuses these companies of sourcing materials from Xinjiang or collaborating with the regional government to exploit ethnic minorities.

Biotechnology is emerging as a competitive field in U.S.-China economic relations. The U.S. Treasury Department is considering restrictions on investments in this sector. China denies the forced labor allegations and criticizes the ban as “political manipulation.” China’s Ministry of Commerce has promised to protect its interests and claims the action undermines bilateral trade relations.

BGI Group disputes the accusations of forced labor. They maintain their operations do not impact U.S. national security as they do not service American patients or access their genetic data. Despite Congress not legislating against BGI, concerns over its ties to China’s government persist. The Pentagon identifies BGI as a Chinese military-associated entity, which affects its reputation.

Recent restrictions fall under the Uyghur Forced Labor Prevention Act, signed into law during President Biden’s administration. The Act followed allegations of human rights abuses against Uyghurs and other minorities in Xinjiang, which the Chinese government disputes. The Trump administration has expanded the blacklist to include numerous Chinese firms allegedly involved in similar practices, stressing the need for fairness in global labor standards.

TAGS: